Literature DB >> 19374944

Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.

Nina E Weisser1, J Christopher Hall.   

Abstract

Antibodies (Abs) are some of the most powerful tools in therapy and diagnostics and are currently one of the fastest growing classes of therapeutic molecules. Recombinant antibody (rAb) fragments are becoming popular therapeutic alternatives to full length monoclonal Abs since they are smaller, possess different properties that are advantageous in certain medical applications, can be produced more economically and are easily amendable to genetic manipulation. Single-chain variable fragment (scFv) Abs are one of the most popular rAb format as they have been engineered into larger, multivalent, bi-specific and conjugated forms for many clinical applications. This review will show the tremendous versatility and importance of scFv fragments as they provide the basic antigen binding unit for a multitude of engineered Abs for use as human therapeutics and diagnostics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19374944     DOI: 10.1016/j.biotechadv.2009.04.004

Source DB:  PubMed          Journal:  Biotechnol Adv        ISSN: 0734-9750            Impact factor:   14.227


  65 in total

1.  Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries.

Authors:  M Medecigo; K Manoutcharian; V Vasilevko; T Govezensky; M E Munguia; B Becerril; A Luz-Madrigal; L Vaca; D H Cribbs; G Gevorkian
Journal:  J Neuroimmunol       Date:  2010-05-06       Impact factor: 3.478

2.  Generation of scFv phages specific to Staphylococcus enterotoxin C1 by panning on related antigens.

Authors:  Anna V Lomonosova; Alexander G Laman; Ksenia K Fursova; Anna O Shepelyakovskaya; Yury V Vertiev; Fedor A Brovko; Evgeny V Grishin
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

Review 3.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

Review 4.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

5.  Correlation Between Protein Primary Structure and Soluble Expression Level of HSA dAb in Escherichia coli.

Authors:  Yankun Yang; Guoqiang Liu; Meng Liu; Zhonghu Bai; Xiuxia Liu; Xiaofeng Dai; Wenwen Guo
Journal:  Food Technol Biotechnol       Date:  2018-03       Impact factor: 3.918

6.  Targeting Colorectal Cancer Cell Lines Using Nanobodies; AgSK1as a Potential Target.

Authors:  Seyed Khalil Rashidi; Seyed Latif Mousavi Gargari; Walead Ebrahimizadeh
Journal:  Iran J Biotechnol       Date:  2017-08-19       Impact factor: 1.671

7.  Computational design of a CNT carrier for a high affinity bispecific anti-HER2 antibody based on trastuzumab and pertuzumab Fabs.

Authors:  Karim Salazar-Salinas; Carlos Kubli-Garfias; Jorge M Seminario
Journal:  J Mol Model       Date:  2012-11-10       Impact factor: 1.810

8.  Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli.

Authors:  Vajihe Akbari; Hamid Mir Mohammad Sadeghi; Abbas Jafrian-Dehkordi; Daryoush Abedi; C Perry Chou
Journal:  J Ind Microbiol Biotechnol       Date:  2014-03-27       Impact factor: 3.346

9.  Optimization modeling of single-chain antibody against hepatoma based on similarity algorithm.

Authors:  Zhi-Jun Zhao; Jing-Tao Chen; Jia-Ying Yuan; Xiao-Xiang Yin; Hua-Yong Song; Xin-Chun Wang
Journal:  Int J Clin Exp Med       Date:  2015-09-15

10.  Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction.

Authors:  Mohammed M Al Qaraghuli; Soumya Palliyil; Gillian Broadbent; David C Cullen; Keith A Charlton; Andrew J Porter
Journal:  BMC Biotechnol       Date:  2015-10-24       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.